FY2027 EPS Estimates for Aspen Aerogels Cut by B. Riley

Aspen Aerogels, Inc. (NYSE:ASPN) – Investment analysts at B. Riley lowered their FY2027 earnings estimates for Aspen Aerogels in a research note issued on Tuesday, November 5th. B. Riley analyst R. Pfingst now forecasts that the construction company will post earnings per share of $1.64 for the year, down from their prior estimate of $1.79. The consensus estimate for Aspen Aerogels’ current full-year earnings is $0.10 per share.

Aspen Aerogels (NYSE:ASPN) last released its quarterly earnings data on Wednesday, August 7th. The construction company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.16. The firm had revenue of $117.80 million during the quarter, compared to the consensus estimate of $101.99 million. Aspen Aerogels had a return on equity of 0.74% and a net margin of 0.39%. Aspen Aerogels’s quarterly revenue was up 144.4% on a year-over-year basis. During the same period last year, the business posted ($0.22) EPS.

ASPN has been the topic of several other reports. StockNews.com upgraded shares of Aspen Aerogels to a “sell” rating in a research report on Thursday, October 31st. Barclays began coverage on shares of Aspen Aerogels in a research report on Tuesday, August 6th. They issued an “overweight” rating and a $27.00 price target on the stock. Benchmark restated a “buy” rating and set a $14.00 price objective on shares of Aspen Aerogels in a research report on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Aspen Aerogels in a report on Wednesday, October 16th. Finally, Roth Mkm reissued a “buy” rating and set a $36.00 price target on shares of Aspen Aerogels in a research report on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.40.

Aspen Aerogels Stock Down 9.0 %

Aspen Aerogels stock opened at $16.85 on Wednesday. Aspen Aerogels has a fifty-two week low of $8.76 and a fifty-two week high of $33.15. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -1,685.00 and a beta of 2.21. The stock’s fifty day moving average is $23.58 and its two-hundred day moving average is $24.66. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.82 and a current ratio of 3.46.

Insiders Place Their Bets

In other news, CFO Ricardo C. Rodriguez sold 32,465 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $30.14, for a total transaction of $978,495.10. Following the completion of the transaction, the chief financial officer now owns 20,790 shares of the company’s stock, valued at $626,610.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, CFO Ricardo C. Rodriguez sold 32,465 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $30.14, for a total value of $978,495.10. Following the sale, the chief financial officer now directly owns 20,790 shares of the company’s stock, valued at approximately $626,610.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Donald R. Young sold 63,355 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $30.03, for a total transaction of $1,902,550.65. Following the transaction, the chief executive officer now directly owns 483,640 shares of the company’s stock, valued at $14,523,709.20. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Aspen Aerogels by 10.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,310 shares of the construction company’s stock worth $341,000 after acquiring an additional 1,339 shares during the last quarter. nVerses Capital LLC increased its position in Aspen Aerogels by 45.0% during the 3rd quarter. nVerses Capital LLC now owns 5,800 shares of the construction company’s stock worth $161,000 after purchasing an additional 1,800 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Aspen Aerogels by 15.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,580 shares of the construction company’s stock valued at $257,000 after buying an additional 1,938 shares during the period. Point72 Hong Kong Ltd acquired a new position in Aspen Aerogels during the second quarter valued at approximately $84,000. Finally, Quent Capital LLC purchased a new stake in Aspen Aerogels during the third quarter worth approximately $118,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Aspen Aerogels Company Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.